Physician Initiated Expanded Access Request for Migalastat in Individual Patients With Fabry Disease

Study of the Effects of Oral AT1001 (Migalastat Hydrochloride) in Patients With Fabry Disease

NCT00925301 ·Status: COMPLETED ·Phase: PHASE3

Open-label Long-term Safety Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease Who Have Completed a Previous AT1001 Study

NCT00526071 ·Status: TERMINATED ·Phase: PHASE2

A Study of Patients With Fabry Disease (US Specific)

NCT06906367 ·Status: RECRUITING

Drug-Drug Interaction Study Between AT1001 (Migalastat Hydrochloride) and Agalsidase in Participants With Fabry Disease

NCT01196871 ·Status: COMPLETED ·Phase: PHASE2

A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Female Participants With Fabry Disease

NCT00304512 ·Status: COMPLETED ·Phase: PHASE2

Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) With Fabry Disease

NCT04049760 ·Status: COMPLETED ·Phase: PHASE3

Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease

NCT01218659 ·Status: COMPLETED ·Phase: PHASE3

A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA Variants

NCT06904261 ·Status: RECRUITING ·Phase: PHASE3

Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged 12 to <18 Years)

NCT03500094 ·Status: COMPLETED ·Phase: PHASE3

French Prospective, Observational Cohort Study of Patients With Fabry Disease Treated With Migalastat

NCT04602364 ·Status: COMPLETED

A Phase I, Randomized, Single-Blind, Four-Period Cross-Over, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Single Oral Doses of GR181413A/AT1001 in Healthy Japanese Subjects

NCT01853852 ·Status: COMPLETED ·Phase: PHASE1

German Observational Multicenter Study of Patients With Fabry Disease Under Chaperone Therapy With Migalastat-HCl.

NCT03135197 ·Status: COMPLETED

Miglustat in Niemann-Pick Type C Disease

NCT00517153 ·Status: COMPLETED ·Phase: PHASE2

Treatment Protocol of Replagal for Patients With Fabry Disease

NCT01031173 ·Status: NO_LONGER_AVAILABLE

Study to Collect Data on Fabry Disease Patients With Enhanceable Alpha-Galactosidase A Activity

NCT00106912 ·Status: COMPLETED

A Safety and Efficacy Study of Fabrazyme® Replacement Therapy in Patients With Cardiac Fabry Disease

NCT00140621 ·Status: COMPLETED ·Phase: PHASE4

A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease

NCT00074971 ·Status: COMPLETED ·Phase: PHASE3

A Study of AT2101 (Afegostat Tartrate) in Adult Patients With Type 1 Gaucher Disease Currently Receiving Enzyme Replacement Therapy

NCT00433147 ·Status: COMPLETED ·Phase: PHASE2

A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease

NCT00081497 ·Status: COMPLETED ·Phase: PHASE4

A Study in Type 1 Gaucher Patients to Evaluate the Pharmacokinetics, Safety and Pharmacodynamics of AT2101

NCT00875160 ·Status: TERMINATED ·Phase: PHASE1

A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease

NCT00196716 ·Status: COMPLETED ·Phase: PHASE2

Extension Study of TKT028 Evaluating Safety and Clinical Outcomes of Replagal® in Adult Patients With Fabry Disease

NCT01124643 ·Status: COMPLETED ·Phase: PHASE3

A Study of Replagal in Treatment-naïve Adults With Fabry Disease

NCT04840667 ·Status: TERMINATED ·Phase: PHASE3

Safety and Efficacy Study of Several Replagal Dosing Regimens on Cardiac Function in Adults With Fabry Disease

NCT00864851 ·Status: COMPLETED ·Phase: PHASE3

Testing Miglustat Administration in Subjects With Spastic Paraplegia 11

NCT04768166 ·Status: COMPLETED ·Phase: PHASE2